MannKind Corporation reports third quarter 2025 revenues of $82.1 million

Reuters11-05

MannKind Corporation reports third quarter 2025 revenues of $82.1 million

MannKind Corporation reported third quarter 2025 revenues of $82.1 million, representing a 17% increase compared to the same period in 2024. Year-to-date 2025 revenues reached $237.0 million, up 14% from year-to-date 2024. As of September 30, 2025, cash, cash equivalents, and investments totaled $286.3 million. In October 2025, the company completed the acquisition of scPharmaceuticals, utilizing approximately $133.2 million of available cash, cash equivalents, and investments, and borrowing an additional $250.0 million in delayed draw term loans. Other business developments include FDA acceptance of the Afrezza supplemental Biologics License Application for pediatric use with a PDUFA date of May 29, 2026, submission of the FUROSCIX ReadyFlow Autoinjector supplemental New Drug Application, and progress in clinical trials for MNKD-101 and MNKD-201.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MannKind Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-265810), on November 05, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581720840?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 21:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581720840","market":"fut","top_or_hot":-1,"title":"MannKind Corporation reports third quarter 2025 revenues of $82.1 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MannKind Corporation reports third quarter 2025 revenues of $82.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MannKind Corporation reported third quarter 2025 revenues of $82.1 million, representing a 17% increase compared to the same period in 2024. Year-to-date 2025 revenues reached $237.0 million, up 14% from year-to-date 2024. As of September 30, 2025, cash, cash equivalents, and investments totaled $286.3 million. In October 2025, the company completed the acquisition of scPharmaceuticals, utilizing approximately $133.2 million of available cash, cash equivalents, and investments, and borrowing an additional $250.0 million in delayed draw term loans. Other business developments include FDA acceptance of the Afrezza supplemental Biologics License Application for pediatric use with a PDUFA date of May 29, 2026, submission of the FUROSCIX ReadyFlow Autoinjector supplemental New Drug Application, and progress in clinical trials for MNKD-101 and MNKD-201.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MannKind Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-265810), on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MannKind Corporation reports third quarter 2025 revenues of $82.1 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMannKind Corporation reports third quarter 2025 revenues of $82.1 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-05 21:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MannKind Corporation reports third quarter 2025 revenues of $82.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MannKind Corporation reported third quarter 2025 revenues of $82.1 million, representing a 17% increase compared to the same period in 2024. Year-to-date 2025 revenues reached $237.0 million, up 14% from year-to-date 2024. As of September 30, 2025, cash, cash equivalents, and investments totaled $286.3 million. In October 2025, the company completed the acquisition of scPharmaceuticals, utilizing approximately $133.2 million of available cash, cash equivalents, and investments, and borrowing an additional $250.0 million in delayed draw term loans. Other business developments include FDA acceptance of the Afrezza supplemental Biologics License Application for pediatric use with a PDUFA date of May 29, 2026, submission of the FUROSCIX ReadyFlow Autoinjector supplemental New Drug Application, and progress in clinical trials for MNKD-101 and MNKD-201.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MannKind Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-265810), on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SCPH","symbol_name":"Scpharmaceuticals Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL2HjNMD:1","article_id":"2581720840","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581720840","pubTimestamp":1762347881,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"MannKind Corporation reported third quarter 2025 revenues of $82.1 million, representing a 17% increase compared to the same period in 2024. Year-to-date 2025 revenues reached $237.0 million, up 14% from year-to-date 2024. As of September 30, 2025, cash, cash equivalents, and investments totaled $286.3 million. In October 2025, the company completed the acquisition of scPharmaceuticals, utilizing approximately $133.2 million of available cash, cash equivalents, and investments, and borrowing an additional $250.0 million in delayed draw term loans. Other business developments include FDA acceptance of the Afrezza supplemental Biologics License Application for pediatric use with a PDUFA date of May 29, 2026, submission of the FUROSCIX ReadyFlow Autoinjector supplemental New Drug Application, and progress in clinical trials for MNKD-101 and MNKD-201.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SCPH":"Scpharmaceuticals Inc.","MNKD":"曼恩凯德生物医疗","BK4139":"生物科技","BK4007":"制药","BK4584":"避孕概念"},"translate_title":"MannKind Corporation报告2025年第三季度收入为8210万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNKD":0.9,"SCPH":0.9},"content_text":"MannKind Corporation reports third quarter 2025 revenues of $82.1 million\n    \n\n        MannKind Corporation reported third quarter 2025 revenues of $82.1 million, representing a 17% increase compared to the same period in 2024. Year-to-date 2025 revenues reached $237.0 million, up 14% from year-to-date 2024. As of September 30, 2025, cash, cash equivalents, and investments totaled $286.3 million. In October 2025, the company completed the acquisition of scPharmaceuticals, utilizing approximately $133.2 million of available cash, cash equivalents, and investments, and borrowing an additional $250.0 million in delayed draw term loans. Other business developments include FDA acceptance of the Afrezza supplemental Biologics License Application for pediatric use with a PDUFA date of May 29, 2026, submission of the FUROSCIX ReadyFlow Autoinjector supplemental New Drug Application, and progress in clinical trials for MNKD-101 and MNKD-201.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MannKind Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-265810), on November 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581720840","isCrawlerRequest":true}